3 Stocks Moving The Drugs Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 25 points (-0.1%) at 17,365 as of Monday, Nov. 3, 2014, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,608 issues advancing vs. 1,366 declining with 174 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Novo Nordisk A/S ( NVO), down 2.4%, Sanofi ( SNY), down 1.4%, Novartis ( NVS), down 1.4% and AstraZeneca ( AZN), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Illumina ( ILMN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Illumina is up $2.63 (1.4%) to $195.21 on average volume. Thus far, 614,769 shares of Illumina exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $192.58-$196.83 after having opened the day at $192.58 as compared to the previous trading day's close of $192.58.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $27.5 billion and is part of the health care sector. Shares are up 74.1% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Illumina a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Allergan ( AGN) is up $2.64 (1.4%) to $192.70 on average volume. Thus far, 1.5 million shares of Allergan exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $188.62-$193.57 after having opened the day at $188.83 as compared to the previous trading day's close of $190.06.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $56.3 billion and is part of the health care sector. Shares are up 70.5% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Allergan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Actavis ( ACT) is up $3.20 (1.3%) to $245.94 on light volume. Thus far, 788,914 shares of Actavis exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $242.33-$247.47 after having opened the day at $242.39 as compared to the previous trading day's close of $242.74.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $64.3 billion and is part of the health care sector. Shares are up 44.5% year-to-date as of the close of trading on Friday. Currently there are 15 analysts who rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE